A new era for castrate resistant prostate cancer: A treatment review and update

Journal of Oncology Pharmacy Practice

Volumn 18, Issue 3, 2012, Pages 343-354

  Fong, Mei Ka ^a   Hare, Ryan ^a   Jarkowski, Anthony ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Castrate resistant; castrate resistant prostate cancer; prostate; treatment

Indexed keywords

ABIRATERONE; CABAZITAXEL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEGARELIX; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; ETOPOSIDE; FOLLITROPIN; GONADORELIN AGONIST; INTERLEUKIN 10; INTERLEUKIN 6; KETOCONAZOLE; LUTEINIZING HORMONE; MEGESTROL ACETATE; MITOXANTRONE; PREDNISONE; PROGESTERONE; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T; STAT3 PROTEIN; TESTOSTERONE; VASCULOTROPIN;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; ANTIANDROGEN THERAPY; ANTIGEN RECOGNITION; BLOOD BRAIN BARRIER; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CHILL; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRY SKIN; DYSLIPIDEMIA; DYSPNEA; EDEMA; ERECTILE DYSFUNCTION; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GENE EXPRESSION; GROWTH; GYNECOMASTIA; HEADACHE; HEPATITIS; HOT FLUSH; HUMAN; HYPERTENSION; HYPOKALEMIA; IMPOTENCE; INSULIN RESISTANCE; LEAN BODY WEIGHT; LEG EDEMA; LEUKOPENIA; LIBIDO DISORDER; LIFE EXPECTANCY; LOW DRUG DOSE; MEDICATION THERAPY MANAGEMENT; METASTASIS; MOOD CHANGE; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OBESITY; OSSIFICATION; OSTEOLYSIS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR SENSITIVITY; REVIEW; SIDE EFFECT; SURVIVAL RATE; TUMOR VOLUME; UPREGULATION; WEIGHT CHANGE;

ANDROSTENOLS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG APPROVAL; HUMANS; MALE; MOLECULAR TARGETED THERAPY; ORCHIECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS; TISSUE EXTRACTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84865623339     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155212437599     Document Type: Review

References (73)

1. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 ; 376: 1147-1154
2. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 ; 363: 411-422
3. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 ; 351: 1502-1512
4. Dawson NA, Conaway M, Halabi S, et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer. 2000 ; 88: 825-834
5. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996 ; 14: 1756-1764
6. AltekruseSFKCKrapchoMNeymanN. (eds) SEER cancer statistics review, 1975-2007. November 2009 SEER data submission, 2010. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975-2007/ (2010, accessed January 2011).
7. Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw. 2010 ; 8: 145-145
8. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002 ; 168: 9-12
9. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002 ; 167: 948-951
10. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008 ; 68: 4447-4454
11. Lamont KR, Tindall DJ. Minireview: alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol. 2011 ; 25: 897-907
12. Nishimura K, Nonomura N, Satoh E, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst. 2001 ; 93: 1739-1746
13. Hendriksen PJ, Dits NF, Kokame K, et al. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res. 2006 ; 66: 5012-5020
14. Mellinghoff IK, Vivanco I, Kwon A, et al. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 2004 ; 6: 517-527
15. Berger R, Lin DI, Nieto M, et al. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res. 2006 ; 66: 5723-5728
16. Waltering KK, Helenius MA, Sahu B, et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res. 2009 ; 69: 8141-8149
17. Ammirante M, Luo JL, Grivennikov S, et al. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010 ; 464: 302-305
18. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006 ; 90: 51-81
19. Culig Z, Steiner H, Bartsch G, et al. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem. 2005 ; 95: 497-505
20. Dillard T, Yedinak CG, Alumkal J, et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010 ; 13: 29-38
21. Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003 ; 423: 506-511
22. De Jong IJ, Eaton A, Bladou F. LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussion. Curr Med Res Opin. 2007 ; 23: 1077-1080
23. Sandow J, Engelbart K, von Rechenberg W. The different mechanisms for suppression of pituitary and testicular function. Med Biol. 1986 ; 63: 192-200
24. Heyns CF, Simonin MP, Grosgurin P, et al. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int. 2003 ; 92: 226-231
25. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989 ; 321: 419-424
26. Schlegel PN, Kuzma P, Frick J, et al. Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin. Urology. 2001 ; 58: 578-582
27. Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007 ; 99: 1516-1524
28. Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw. 2010 ; 8: 211-223
29. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002 ; 87: 599-603
30. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006 ; 24: 4448-4456
31. Dockery F, Bulpitt CJ, Agarwal S, et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003 ; 104: 195-201
32. Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007 ; 110: 1493-1500
33. Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000 ; 163: 181-186
34. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005 ; 352: 154-164
35. Yee EF, White RE, Murata GH, et al. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med. 2007 ; 22: 1305-1310
36. Qaseem A, Snow V, Shekelle P, et al. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008 ; 148: 680-684
37. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004 ; 96: 879-882
38. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003 ; 169: 2008-2012
39. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009 ; 361: 745-755
40. Plenaxis (package insert). Waltham, MA: Praecis Pharmaceuticals ; 2005:
41. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008 ; 102: 1531-1538
42. Gomella LG. Effective testosterone suppression for prostate cancer: is there a best castration therapy?. Rev Urol. 2009 ; 11: 52-60
43. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 ; 25: 1596-1605
44. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004 ; 22: 1025-1033
45. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999 ; 17: 2506-2513
46. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol. 1997 ; 15: 382-388
47. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer. 1995 ; 76: 1428-1434
48. Culig Z, Bartsch G, Hobisch A. Antiandrogens in prostate cancer endocrine therapy. Curr Cancer Drug Targets. 2004 ; 4: 455-461
49. Sartor AO, Tangen CM, Hussain MH, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer. 2008 ; 112: 2393-2400
50. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004 ; 22: 1025-1033
51. Pfizer Inc Estramustine (package insert). New York, NY: Pfizer Inc ; 2007:
52. Spitaleri G, Matei DV, Curigliano G, et al. Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer. Ann Oncol. 2009 ; 20: 498-502
53. Caffo O, Sava T, Comploj E, et al. Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. Urol Oncol. 2010 ; 28: 152-156
54. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 ; 351: 1513-1520
55. Machiels JP, Mazzeo F, Clausse M, et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2008 ; 26: 5261-5268
56. Seattle, WA: Dendreon Corporation ; 2010.
57. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 ; 363: 411-422
58. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 ; 24: 3089-3094
59. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009 ; 115: 3670-3679
60. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009 ; 15: 723-730
61. Ozguroglu M, Oudard S, Sartor AO, et al. Effect of G-CSF prophylaxis on the ccurrence of neutropenia in men receiving cabazitaxel plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the TROPIC study. J Clin Oncol. 2011 ; 29 (Suppl. 7). Abstract 144 - Abstract 144
62. Jevtana (package insert). Bridgewater, NJ: Sanofi-Avenis ; 2010:
63. Grigoryev DN, Long BJ, Nnane IP, et al. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo. Br J Cancer. 1999 ; 81: 622-630
64. Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005 ; 96: 1241-1246
65. Yap TA, Carden CP, Attard G, et al. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol. 2008 ; 8: 449-457
66. Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab. 2009 ; 94: 3623-3630
67. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010 ; 28: 1496-1501
68. Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010 ; 28: 1481-1488
69. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 ; 364: 1995-2005
70. Cougar Biotechnology. Neoadjuvant abiraterone acetate plus leuprolide acetate in men with localized high risk prostate cancer. NLM identifier no. NCT00924469, 2009. Bethesda, MD: National Library of Medicine (US). http://clinicaltrials.gov/ct2/show/NCT00924469 (2009, accessed 8 November 2010).
71. Fred Hutchinson Cancer Research Center. Abiraterone acetate, prednisone, and leuprolide acetate or goserelin before and during radiation therapy in treating patients with localized or locally advanced prostate cancer. NLM identifier no. NCT01023061, 2009. Bethesda, MD: National Library of Medicine (US). http://clinicaltrials.gov/ct2/show/NCT01023061 (2009, accessed 8 November 2010).
72. Logothetis C, de Bono JS, Molina A, et al. Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): results from the COU-AA-301 phase III study. J Clin Oncol. 2011 ; 29 (Suppl). Abstr 4520 - Abstr 4520
73. Cougar Biotechnology. A phase 3, randomized, double-blind, placebo-controlled study of abiraterone acetate (CB7630) plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer. NLM identifier no. NCT00887198, 2009. Bethesda, MD: National Library of Medicine (US). http://clinicaltrials.gov/NCT00887198 (2009, accessed 2 January 2012).